| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac9f22bc3bc8655b7477baf87e628a5c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate |
2013-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8816756f7804b3b98fcd42b2134b1e0e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_349d105c3f288dc561053ee037bd6d8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18bee7650994ae9ac84cb7ac7c639212 |
| publicationDate |
2014-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20140147836-A |
| titleOfInvention |
Inhibitors of human ezh2, and methods of use thereof |
| abstract |
The present invention relates to the inhibition of the wild-type and specific mutant forms of the human histone methyltransferase EZH2, a catalytic subunit of the PRC2 complex that catalyzes the monomethylation or trimerisation of lysine 27 (H3-K27) on histone H3 . In one embodiment, the inhibition is selective for the mutant form of EZH2, whereby the trimethylation of H3-K27 associated with a particular cancer is inhibited. This method can be used to treat cancers including follicular lymphoma and diffuse large B cell lymphoma (DLBCL). It also provides methods for identifying small molecule selectivity inhibitors of the mutant form of EZH2, and methods for measuring the reactivity to EZH2 inhibitors in a subject. |
| priorityDate |
2012-03-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |